Discover what is our current strategy and main research platforms
Corporate Slide deck
What is the difference between autologous and allogeneic CAR T-cell therapies?
Allogeneic vs. Autologous Fact Sheet
What is NKG2D and where is it expressed?
NKG2D Fact Sheet
What is the shRNA technology and how can it be used for allogeneic cell therapies?
shRNA Fact Sheet
What is multiplexing of shRNAs and why is that important?
Multiplexing shRNA Fact Sheet
Dual targeting CAR T-cells: what for?
Dual CAR Fact Sheet
What is B7-H6 and where is it expressed?
B7-H6 Fact Sheet
What is the TIM Technology included in CYAD-101?
TIM Fact Sheet
What are the differences between CAR T-cell and CAR NK cell therapies?
CAR T vs NK Cells
Hairpins and Scissors – Delivering a Non-Gene Edited Allogeneic CAR T Cell Therapy for the Masses White Paper (2020)
White Paper
Development of the Next Generation NKG2D CAR T-cell Manufacturing Process White Paper (2019)
CAR T NKR-2: Leveraging the Breadth of Innate Immunity White Paper (2017)
Celyad Oncology Logo
